Tafenoquine

Generic Name: Tafenoquine

Brand Names: Arakoda, Krintafel

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₈F_₃N_₃O_₃

CAS Number: 106635-80-7

Unique Ingredient Identifier: 262P8GS9L9

Background: Tafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group. It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria. Tafenoquine was further developed collaboratively between GlaxoSmithKline and Medicines for Malaria Venture. It was FDA approved on July 20, 2018.

Indication: 用于16岁及以上疟疾患者，根治(预防复发)由间日疟原虫(P.vivax)导致的疟疾。

Associated Conditions: Malaria caused by plasmodium vivax

Clinical Trials

Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil

Active, not recruiting

Conditions: Malaria, Vivax
G6PD Deficiency

Interventions: Drug: Primaquine
Drug: Tafenoquine

First Posted Date: 2021-10-27

Last Posted Date: 2023-06-13

Lead Sponsor: Fundação de Medicina Tropical Dr. Heitor Vieira Dourado

Target Recruit Count: 16000

Registration Number: NCT05096702

Locations: 🇧🇷
Grande Vitória, Manaus, AM, Brazil
🇧🇷
Efigênio Salles (UBSR), Manaus, AM, Brazil
🇧🇷
Cooperativa I, Manaus, AM, Brazil

and more 38 locations

Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPAQ in Mali

Phase 2

Completed

Conditions: Malaria,Falciparum

Interventions: Drug: Sulphadoxine-pyrimethamine with amodiaquine
Drug: Artemether-lumefantrine
Drug: Primaquine Phosphate
Drug: Tafenoquine

First Posted Date: 2021-10-18

Last Posted Date: 2022-01-18

Lead Sponsor: London School of Hygiene and Tropical Medicine

Target Recruit Count: 80

Registration Number: NCT05081089

Locations: 🇲🇱
Malaria Research and Training Centre, Bamako, Mali

Tafenoquine and Primaquine in Colostrum and Breast Milk

Phase 4

Withdrawn

Conditions: Healthy Lactating Women

Interventions: Drug: Primaquine
Drug: Tafenoquine

First Posted Date: 2021-08-02

Last Posted Date: 2024-04-04

Lead Sponsor: University of Oxford

Registration Number: NCT04984759

Locations: 🇹🇭
Shoklo Malaria Research Unit (SMRU), Mae Sot, Tak, Thailand

Southeast Asia Dose Optimization of Tafenoquine

Phase 4

Recruiting

Conditions: Plasmodium Vivax Malaria

Interventions: Drug: Tafenoquine
Drug: Chloroquine
Drug: Artemether 20 mg-Lumefantrine 120 mg

First Posted Date: 2021-01-12

Last Posted Date: 2025-03-06

Lead Sponsor: University of Oxford

Target Recruit Count: 700

Registration Number: NCT04704999

Locations: 🇱🇦
Lao Oxford Mahosot Hospital Wellcome Trust Research Unit (LOMWRU), Vientiane, Lao People's Democratic Republic
🇻🇳
Oxford University Clinical Research Unit (OUCRU), Binh Phuoc, Vietnam
🇰🇭
Mahidol Oxford Tropical Medicine Research Unit (MORU), Cambodia, Siem Reap, Cambodia

and more 2 locations

Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2)

Phase 2

Completed

Conditions: Malaria, Falciparum

Interventions: Drug: Dihydroartemisinin/Piperaquine
Drug: Tafenoquine 100mg [Arakoda]

First Posted Date: 2020-10-30

Last Posted Date: 2022-06-09

Lead Sponsor: London School of Hygiene and Tropical Medicine

Target Recruit Count: 80

Registration Number: NCT04609098

Locations: 🇲🇱
Malaria Research and Training Centre, Bamako, Mali

Tafenoquine in Patients With Mild to Moderate COVID-19

Phase 2

Completed

Conditions: COVID 19 Disease

Interventions: Drug: Placebo
Drug: Tafenoquine Oral Tablet

First Posted Date: 2020-08-31

Last Posted Date: 2025-01-07

Lead Sponsor: 60 Degrees Pharmaceuticals LLC

Target Recruit Count: 86

Registration Number: NCT04533347

Locations: 🇺🇸
Skyline Medical Center, Elkhorn, Nebraska, United States
🇺🇸
AFC Urgent Care, Easley, South Carolina, United States
🇺🇸
F&T Medical Research, Inc., Miami, Florida, United States

and more 7 locations

Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine

Phase 3

Completed

Conditions: Vivax Malaria
Plasmodium Vivax
Malaria, Vivax
Malaria Relapse

Interventions: Drug: Primaquine
Drug: Tafenoquine

First Posted Date: 2020-06-02

Last Posted Date: 2024-10-07

Lead Sponsor: Menzies School of Health Research

Target Recruit Count: 960

Registration Number: NCT04411836

Locations: 🇵🇰
Aga Khan Hospital Karachi, Karachi, Pakistan
🇰🇭
Kravanh District Hospital, Pursat, Pursat Province, Cambodia
🇰🇭
Siem Pang Health Centre, Stung Treng, Cambodia

and more 3 locations

Long-Term Safety Study of Tafenoquine

Phase 2

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Tafenoquine
Other: Placebo

First Posted Date: 2017-10-25

Last Posted Date: 2021-08-26

Lead Sponsor: 60 Degrees Pharmaceuticals LLC

Target Recruit Count: 600

Registration Number: NCT03320174

Locations: 🇺🇸
Valley Retina Institute, McAllen, Texas, United States
🇦🇺
Linear Clinical Research, Nedlands, Western Australia, Australia
🇺🇸
Retina Consultants of Southern Colorado, Colorado Springs, Colorado, United States